Low-grade oligodendroglioma responds to chemotherapy
Low-grade oligodendroglioma responds to chemotherapy
复制标题
DOI：
10.1212/wnl.46.1.203
复制
发表时间：
1996-01-01
期刊：
影响因子：
9.9
通讯作者：
DeAngelis, LM
中科院分区：
文献类型：
--
作者：
Mason, WP;Krol, GS;DeAngelis, LM
我们对9例有症状的低级别少突胶质细胞瘤患者进行了标准和强化的丙卡巴肼、洛莫司汀（CCNU）和长春新碱化疗。8例患者在就诊时接受了化疗，1例在放疗失败后接受了复发治疗。根据临床或MRI标准或两者，所有患者均改善。在治疗过程中没有患者恶化，并且在就诊时接受治疗的所有存活患者中，在没有放疗的情况下，反应持续了中位35个月（范围，22-45）。化疗耐受良好;所有患者均出现骨髓抑制，但只有接受强化方案的患者需要减少剂量或提前停止治疗。与复发性和间变性少突胶质细胞瘤一样，低级别少突胶质细胞瘤对化疗有反应。
We administered chemotherapy in standard and intensified formulations of procarbazine, lomustine (CCNU), and vincristine to nine symptomatic patients with low-grade oligodendroglioma. Eight patients were treated with chemotherapy at presentation and one was treated for a recurrence after radiotherapy had failed. All patients improved by clinical or MRI criteria, or both. No patient deteriorated while in therapy and the responses were sustained without radiotherapy for a median of 35 months (range, 22-45) in all surviving patients treated at presentation. Chemotherapy was well tolerated; all patients developed myelosuppression, but only those receiving the intensified regimen required dose reduction or premature discontinuation of treatment. As with recurrent and anaplastic oligodendroglioma, low-grade oligodendroglioma responds to chemotherapy.